Differences between Type 1 and Type 2 Diabetes.

Diabetes, or diabetes mellitus (DM), is a metabolic disorder in which the body cannot properly store and use sugar.

It affects the body's ability to use glucose, a type of sugar found in the blood, as fuel. This happens because the body does not produce enough insulin, or the cells do not correctly respond to insulin to use glucose as energy.

Insulin is a type of hormone produced by the pancreas to regulate how blood sugar becomes energy. An imbalance of insulin or resistance to insulin causes diabetes.

Diabetes is linked to a higher risk of cardiovascular disease, kidney disease, vision loss, neurological conditions, and damage to blood vessels and organs.

There is type 1, type 2, and gestational diabetes. They have different causes and risk factors, and different lines of treatment.

This article will compare the similarities and differences of types 1 and 2 diabetes.

People with type 1 diabetes will require supplemental insulin on an

ongoing basis. People with type 2 will likely only need this for the later

stages of the condition. A healthcare specialist will be able to test

a patient for diabetes, even if type 2 diabetes shows no symptoms.

Read more: Differences between Type 1 and Type 2 Diabetes.

Source: MedicalNewsToday

Serum Level Measurements Improve Disease Risk Prediction.

Results obtained by using a commercially available uromodulin ELISA kit to analyze serum samples from individuals at risk for heart and circulatory system diseases indicated that this kidney-specific protein is a biomarker not only for kidney disease but also for cardiovascular diseases.

The glycoprotein uromodulin, also known as Tamm-Horsfall protein (THP), is synthesized exclusively in the kidneys and subsequently secreted. Low uromodulin concentrations in serum are a sensitive indicator for a loss of kidney function and thus play a role in the diagnosis of various renal diseases (nephropathies). When renal function is impaired, the uromodulin concentration in the serum sinks rapidly. Therefore, renal functional disorders can be identified at a very early stage of kidney damage, even in cases with few symptoms.

Uromodulin -a biomarker not only for kidney disease but also for cardiovascular diseases.

Read more: Serum Level Measurements Improve Disease Risk Prediction.

Source: LabMedica

Download in PDF

Screen Your Blood Cholesterol Levels For Your Heart Disease Risk!

Researchers have developed a first-of-its-kind rapid assay for measuring effectiveness of a patient’s high-density lipoprotein cholesterol (HDL-C) in cleaning up arterial cholesterol. This HDL-C function test could improve risk assessment and diagnosis, and help provide and monitor more personalized treatments for cardiovascular disease (CVD) patients.

Image: Research suggests a HDL-C function test could improve risk assessment and diagnosis,
and help provide and monitor more personalized treatments for CVD patients
(Photo courtesy of iStock).

While scientists have yet to fully elucidate how HDL-C helps protects against heart disease, one of its chief functions is thought to be mediating the removal of cholesterol from blood vessel walls. Recent studies have indicated that the ability of a patient’s HDL-C to do this – known as its cholesterol efflux capacity (CEC) – is a better gauge of CVD development than HDL-C levels on their own. This means, for example, that a patient with low levels of HDL-C but optimal CEC could be protected against heart disease to a greater degree than a patient with high levels of HDL-C but low CEC. However, the current standard research procedures for measuring CEC involve radioisotope-labeled cholesterol and cultured macrophages, making these methods too complex and time-consuming for clinical testing.

In this study, a team of researchers led by Amane Harada, PhD, of Sysmex Corporation (Kobe, Japan) and Ryuji Toh, MD, PhD, of Kobe University Graduate School of Medicine (Kobe, Japan) has developed a test for HDL-C function that is simple enough for clinical use. With a turnaround time of less than 6 hours, the test determines cholesterol uptake capacity (CUC) – the ability of HDL-C to accept additional cholesterol – which the researchers found correlates with CEC but is easier to measure. 

They evaluated their CUC test in 156 patients who had undergone revascularization (such as a stent or bypass) due to coronary artery disease and who had subsequently decreased their low-density lipoprotein cholesterol to a healthier level of less than 100 mg/dL. The study found that low CUC in these patients after treatment was significantly associated with the recurrence of coronary lesions. The researchers also determined that combining CUC with established CVD risk factors significantly improved the power of established factors to forecast which patients would redevelop heart disease.

If further trials validate this test, it could enable healthcare providers to use CUC in conjunction with HDL-C levels to better predict who is at risk for CVD onset or recurrence. This test could also be used to develop new treatments that increase CEC and to monitor their efficacy in patients.

“A more efficient enhancement of the atheroprotective functions of HDL may decrease the risk of atherosclerosis and [cardiovascular disease], although it has been difficult to develop therapeutic drugs with the expected effects,” wrote Harada and Toh in this paper, “We consider that this can be explained in part by the lack of a convenient assay system to evaluate HDL functionality without complicated or time-consuming procedures. In this respect, our cholesterol uptake assay provides a concise, accurate, and robust system for high-throughput analysis at low cost.”

The study, by Harada A et al, was published in the May 2017 issue of the Journal of Applied Laboratory Medicine.

Source: labmedica

Cardiac Biomarkers and Clinical Decision Making

New video discusses the importance of cardiac biomarkers

Click to watch video

In this video, hear from a former operating engineer at the White House who, despite an active lifestyle and basic good health, experienced sudden heart failure. In the context of his healthcare journey, the video highlights the role of cardiac biomarkers in clinical decision making and the diagnosis of a heart attack.

Diagnosed with advanced coronary artery disease, the patient underwent cardiac bypass surgery and was enrolled in a biomarker study during his postoperative course of treatment. “There’s no doubt that biomarkers have completely transformed how we care for our patients in cardiovascular medicine,” says the patient’s cardiologist.

MicroRNA: A Tiny Molecule Yields Big Insights Into Disease States

Regular readers of this column will know that there are two main categories of nucleic acids—DNA and RNA. They’ll also know that while for living organisms DNA acts as the genetic data repository, RNA has a messenger role (mRNAs, transcribed from DNA to direct protein synthesis). Most will also recall that there are other classes of RNA molecules, particularly tRNAs (used to tag and identify amino acids for protein synthesis) and rRNAs (structural components of the ribosome, the cellular “machinery” for protein synthesis). In addition to these, there’s increasing interest in the molecular diagnostics community in a less widely known but no less common RNA form, the microRNA or miRNA.

Read more: MicroRNA: A Tiny Molecule Yields Big Insights Into Disease States

Source: MedicalLaboratoryObserver

The Best Medicine Against Cholesterol And High Blood Pressure

Cholesterol is a waxy substance that comes from two sources: your body and food. Excess cholesterol can form plaque between layers of artery walls, making it harder for your heart to circulate blood.

Plaque can break open and cause blood clots. If a clot blocks an artery that feeds the brain, it causes a stroke. If it blocks an artery that feeds the heart, it causes a heart attack.

Heart disease, stroke and other cardiovascular diseases are among the leading cause of death and now kill more than 800,000 adults in the US each year. Two main reasons people have heart disease or stroke are high blood pressure and cholesterol.

Read more: The Best Medicine Against Cholesterol And High Blood Pressure

Source: herb-cookbook

Heart Transplantation Recipients Unaffected by Donor Troponin Levels

Many transplant centers routinely reject hearts if the donor’s blood test reveals elevated levels of troponin I, a protein found in heart muscle that enters the bloodstream when there is a heart attack or other heart muscle damage. Donors with previous heart disease are automatically excluded.

Heart transplantation is one of the greatest achievements in modern medicine and patients with advanced heart failure in whom survival is measured in weeks and months are offered the potential for survival of equal to or greater than 10 years with excellent quality of life.

Read more: Heart Transplantation Recipients Unaffected by Donor Troponin Levels

According to new research, a blood test that leads to donor hearts being rejected may not effectively
predict whether a heart transplant will succeed or fail (Photo courtesy of the AMA).

Source: labmedica

Simple At-Home Test Developed To Detect Blood Clots

Researchers have developed a simple paper-based screening method that can help patients with blood clotting disorders perform regular tests from the convenience of their homes.

The screening test created by researchers at the University of Cincinnati (UC) could be a game changer for patients with several life-threatening conditions, researchers said.

Patients with cardiovascular disease, hypertension, atrial fibrillation, congestive heart failure, kidney disease and others who are at risk for blood clotting are especially vulnerable when blood-thinning medication levels get too weak or too strong, they said.

This imbalance can quickly lead to ischemic (clotting) or hemorrhagic (bleeding) strokes if not detected in time.

"We have developed a blood screening device for patients on medications like Coumadin, warfarin or other blood thinners who need to monitor their blood-clotting levels on a regular basis," said Andrew Steckl, UC professor of electrical engineering in the College of Engineering and Applied Science.

Read more: Simple At-Home Test Developed To Detect Blood Clots

The simple technology also help patients who have a known inherited blood clotting disorder detect
concerning levels early. (Representational Image)

Source: ndtv

Tips to diabetes for drinking alcohol

Enjoying a glass of wine, fruity margarita, or frosty pint of beer requires a little forethought if you have diabetes. Before you indulge, make sure you have a tasty appetizer or healthy salad to go along with your drink. And talk to your doctor about drinking alcohol. The answer to whether you can or should not will depend on your specific circumstances.

How Does Alcohol Affect Blood Sugar?

The way alcohol affects your blood sugar comes down to whether you’ve eaten, and how much and how often you drink. A standard drink contains 0.6 fluid ounces of alcohol. This means that a 12 ounce beer (about 5% alcohol) is equivalent to a 5 ounce glass of your average table wine (about 12% alcohol) or a shot of hard liquor such as vodka. Here’s the scoop on how much and how often:

• When you have an occasional drink with food, alcohol generally has little effect on your blood sugar. This is the safest way to enjoy alcohol.
• When you have an occasional drink without any food, alcohol can cause your blood sugar to fall to dangerously low levels. You should never drink alcohol on an empty stomach.
• If you are a habitual drinker (3 to 4 drinks a day), alcohol increases your blood sugar no matter what you eat. If this describes you, consider talking to your doctor about ways to cut back or stop your alcohol use.

Read more: Tips to diabetes for drinking alcohol

Source: diabeteszone

Atherosclerosis, Rheumatoid Arthritis and Inflammation.

Rheumatoid arthritis (RA) has long been associated with increased cardiovascular risk, but despite substantial improvements in disease management, mortality remains high. Atherosclerosis is more prevalent in RA than in the general population, and atherosclerotic lesions progress at a faster rate and might be more prone to rupture, causing clinical events. Cells and cytokines implicated in RA pathogenesis are also involved in the development and progression of atherosclerosis, which is generally recognized as an inflammatory condition. The two diseases also share genetic and environmental risk factors, which suggests that patients who develop RA might also be predisposed to developing cardiovascular disease. In RA, inflammation and atherosclerosis are closely linked. Inflammation mediates its effects on atherosclerosis both through modulation of traditional risk factors and by directly affecting the vessel wall. Treatments such as TNF inhibitors might have a beneficial effect on cardiovascular risk. However, whether this benefit is attributable to effective control of inflammation or whether targeting specific cytokines, implicated in atherosclerosis, provides additional risk reduction is unclear. Further knowledge of the predictors of cardiovascular risk, the effects of early control of inflammation and of drug-specific effects are likely to improve the recognition and management of cardiovascular risk in patients with RA.

Rheumatoid arthritis (RA) is associated with a significantly increased risk of cardiovascular mortality, accounted for mainly by increased atherosclerotic disease.1, 2 Although the prevalence of some traditional cardiovascular risk factors is increased in RA, adjustment for these factors does not fully account for the heightened risk, suggesting that RA itself is an independent risk factor for cardiovascular disease (CVD).3 The prevalence of atherosclerosis is increased in RA, even in early disease,4 and chronic inflammation is thought to promote atherosclerosis both by modulation of traditional risk factors and also possibly by direct biological effects on the artery. In this article, we discuss the potential mechanisms that might accelerate atherosclerosis in RA, with a particular focus on inflammation.

Read more: Atherosclerosis, Rheumatoid Arthritis and Inflammation.

Figure 2: Development of an atherosclerotic plaque.

Source: NatureReviewsRheumatology